Locations
Cambridge, MA, USA · Seattle, WA, USA
industry
Biotechnology
Size
51 - 200 employees
Stage
Series A
founded in
2020
Gentibio, inc., is an early stage biotherapeutics company co-founded by pioneers in treg biology and synthetic immunology to develop engineered regulatory t cells (engtregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. Gentibio's proprietary autologous and allogeneic engtregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory t-cell therapeutics. Gentibio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.
Something looks off?